scholarly journals Diagnostic Value of Plasma miR-181b, miR-196a, and miR-210 Combination in Pancreatic Cancer

2020 ◽  
Vol 2020 ◽  
pp. 1-6
Author(s):  
Gongpan Liu ◽  
Cunhua Shao ◽  
Anyun Li ◽  
Xiaobin Zhang ◽  
Xingjun Guo ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Vascular Invasion ◽  
Operating Characteristic ◽  
Clinical Stage ◽  
Diagnostic Value ◽  
Carbohydrate Antigen ◽  
Plasma Samples ◽  
Healthy Individuals ◽  
Qrt Pcr ◽  
Node Metastasis

Purpose. This study was aimed at investigating the roles of plasma miR-181b, miR-196a, and miR-210 in the diagnosis of pancreatic cancer (PC). Methods. Plasma samples were isolated from 40 patients with PC and 40 healthy individuals, respectively. The expression of miR-181b, miR-196a, and miR-210 was detected by qRT-PCR. The level of carbohydrate antigen 199 (CA199) was measured by an electrochemiluminescence (ECL) assay. The receiver operating characteristic (ROC) curve was used to analyze the diagnostic value of miR-181b, miR-196a, miR-210, CA199, and their combinations in PC. Results. The expression of plasma miR-181b, miR-196a, and miR-210 was significantly upregulated in PC patients. The plasma level of CA199 was also significantly increased in PC patients. The expression of miR-181b, miR-196a, and miR-210 was closely associated with lymph node metastasis, clinical stage, and vascular invasion but not correlated with age, gender, and tumor size. miR-181b, miR-196a, and miR-210 have lower AUC than CA199 in the diagnosis of PC. miR-181b+miR-210 and miR-196a+miR-210 also have lower AUC than CA199. It is worth noting that miR-181b+miR-196a+miR-210 has a higher AUC than CA199 in the diagnosis of PC. Conclusion. The combination of plasma miR-181b, miR-196a, and miR-210 had a good diagnostic value for PC.

The early diagnostic value of combined detection of plasma miR-181b, miR-196a and miR-210 in pancreatic cancer

2019 ◽  
Author(s):  
Gongpan Liu ◽  
Cunhua Shao ◽  
Anyun Li ◽  
Xiaobin Zhang ◽  
Xingjun Guo ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Early Diagnosis ◽  
Operating Characteristic ◽  
Clinical Stage ◽  
Diagnostic Value ◽  
Carbohydrate Antigen ◽  
Healthy Individuals ◽  
Diagnostic Efficacy ◽  
Lymph Nodes Metastasis ◽  
Combined Detection

Abstract Background This study aimed to investigate the effect of combination of plasma miR-181b, miR-196a and miR-210 on early diagnosis of pancreatic cancer (PC).Methods In our study, the plasma was isolated from patients with PC and healthy individuals, respectively. The expressions of miR-181b, miR-196a and miR-210 were detected by qRT-PCR. Moreover, the level of carbohydrate antigen 199 (CA199) was measured by electrochemiluminescence (ECL) assay. Furthermore, the area under the receiver operating characteristic (ROC) curve (AUC) was used to analyze the diagnostic efficacy of miR-181b, miR-196a, miR-210 and CA199, as well as the combination of thses miRNAs in early PC patients and healthy individuals.Results The expressions of miR-181b, miR-196a and miR-210 were significantly upregulated in PC patients. In addition, the level of CA199 was also significantly upregulated in the plasma of PC patients. The expressions of miR-181b, miR-196a and miR-210 were closely associated with lymph nodes metastasis, clinical stage and vascular invasion, but had no correlation with the patient's age, gender and tumor size. Moreover, miR-181b, miR-196a and miR-210 have lower AUC than CA199 in PC patients. The combinations miR-181b + miR-196a, miR-181b + miR-210, miR-196a + miR-210 also have lower AUC than CA199 in PC patients. It is worth noting that the combinations miR-181b + miR-196a + miR-210 have higher AUC than CA199 in PC.Conclusions Our study demonstrated that the combination of plasma miR-181b, miR-196a and miR-210 had good value for PC early diagnosis.

scholarly journals Down-regulation of miR-539 indicates poor prognosis in patients with pancreatic cancer

2019 ◽  
Vol 13 (1) ◽  
pp. 497-503 ◽  
Author(s):  
Haibo Yu ◽  
Hongliang Song ◽  
Zhongwu Ma ◽  
Wu Ji
Keyword(s):  
Pancreatic Cancer ◽  
Clinical Stage ◽  
Prognostic Indicator ◽  
Expression Level ◽  
Chain Reaction ◽  
Down Regulation ◽  
Qrt Pcr ◽  
Node Metastasis ◽  
Polymerase Chain ◽  
Well Differentiated

AbstractIt has been demonstrated that miR-539 plays an important role in the development and progression of tumors. The purpose of this study was to analyze the correlation between the expression level of miR-539 and the clinicopathological features and prognosis of patients with pancreatic cancer. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to analyze the expression level of miR-539 in 60 patients with pancreatic cancer. It was found that miR-539 gene expression was down-regulated in pancreatic cancer compared with that in paracancerous tissues. In addition, the expression level of miR-539 was inversely correlated with tumor differentiation (poorly to moderately differentiated vs. well differentiated, P=0.006), lymph node metastasis (positive vs. negative, P=0.006), clinical stage (III-IV vs. I-II, P=0.002), CA199 (≥200 vs. <200, P=0.019) and distant metastasis (positive vs. negative, P=0.035). The survival time of pancreatic cancer patients with low expression of miR-539 was significantly shorter than that of patients with high expression of miR-539. Multivariate analysis suggested that miR-539 expression level was an independent prognostic indicator for patients with pancreatic cancer (P=0.025). Down-regulation of miR-539 may be a potentially unfavorable prognostic factor for patients with pancreatic cancer, and further studies are needed to confirm our conclusion in the future.

scholarly journals Arginase 1 (Arg1) as an Up-Regulated Gene in COVID-19 Patients: A Promising Marker in COVID-19 Immunopathy

2021 ◽  
Vol 10 (5) ◽  
pp. 1051 ◽  
Author(s):  
Afshin Derakhshani ◽  
Nima Hemmat ◽  
Zahra Asadzadeh ◽  
Moslem Ghaseminia ◽  
Mahdi Abdoli Shadbad ◽  
...  
Keyword(s):  
Immune Responses ◽  
Whole Blood ◽  
Roc Analysis ◽  
Operating Characteristic ◽  
Rna Extraction ◽  
Diagnostic Value ◽  
Healthy Individuals ◽  
Cdna Synthesis ◽  
Arginase 1 ◽  
Global Pandemic

Background: The coronavirus disease 2019 (COVID-19) outbreak, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared a global pandemic. It is well-established that SARS-CoV-2 infection can lead to dysregulated immune responses. Arginase-1 (Arg1), which has a pivotal role in immune cells, can be expressed in most of the myeloid cells, e.g., neutrophils and macrophages. Arg1 has been associated with the suppression of antiviral immune responses. Methods: Whole blood was taken from 21 COVID-19 patients and 21 healthy individuals, and after RNA extraction and complementary DNA (cDNA) synthesis, gene expression of Arg1 was measured by real-time PCR. Results: The qPCR results showed that the expression of Arg1 was significantly increased in COVID-19 patients compared to healthy individuals (p < 0.01). The relative expression analysis demonstrated there were approximately 2.3 times increased Arg1 expression in the whole blood of COVID-19 patients. Furthermore, the receiver operating characteristic (ROC) analysis showed a considerable diagnostic value for Arg1 expression in COVID-19 (p = 0.0002 and AUC = 0.8401). Conclusion: Arg1 might be a promising marker in the pathogenesis of the disease, and it could be a valuable diagnostic tool.

scholarly journals Expression Analysis of Circulating miR-22, miR-122, miR-217 and miR-367 as Promising Biomarkers of Acute Lymphoblastic Leukemia

2021 ◽  
Author(s):  
Fatemeh hosseinpour-soleimani ◽  
Gholamreza Khamisipour ◽  
Zahra Derakhshan ◽  
Bahram Ahmadi
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Roc Analysis ◽  
Operating Characteristic ◽  
Lymphoblastic Leukemia ◽  
Area Under The Curve ◽  
Diagnostic Value ◽  
Healthy Individuals ◽  
Quantitative Real Time Pcr ◽  
Expression Levels

Abstract Background Currently, the role of serum-based biomarkers such as microRNAs in cancer diagnosis has been extensively established. This study aimed to determine expression levels of bioinformatically selected miRNAs and whether they can be used as biomarkers or a new therapeutic target in patients with Acute Lymphoblastic Leukemia (ALL). Materials and Methods The expression levels of serum miR-22, miR-122, miR-217, and miR-367 in 21 ALL patients and 21 healthy controls were measured using quantitative real-time PCR. The receiver operating characteristic (ROC) curve and the associated area under the curve (AUC) was used to assess candidate miRNAs' diagnostic value as a biomarker. Results The results showed that miR-217 was markedly decreased in patients with ALL compared to controls. Moreover, miR-22, miR-122, and miR-367 were found to be upregulated. Furthermore, ROC analysis showed that serum miR-217 and miR-367 could differentiate ALL patients from the healthy individuals, while miR-22 has approximate discriminatory power that requires further investigation. Conclusion Collectively, the results suggested that miR-217 may play a tumor suppressor role in ALL, whereas miR-22, miR-122, and miR-367 could function as an oncogene. Overall, miR-22, miR-217, and miR-367 could be considered possible biomarkers for the early diagnosis of ALL.

SOX9 stands for a bio-marker for prostate cancer detection

2020 ◽  
Author(s):  
Hao Zi ◽  
Wen-Lin Tao ◽  
Lei Gao ◽  
Zhao-Hua Yu ◽  
Xiao-Dong Bai ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Detection ◽  
Roc Curve ◽  
Operating Characteristic ◽  
Diagnostic Value ◽  
Quantitative Real Time Pcr ◽  
Optimal Cutoff ◽  
Qrt Pcr ◽  
Incidence And Mortality ◽  
The Relationship

Abstract Background Prostate cancer is one of common cancers around the world, and in our country the incidence and mortality of PCa are both increasing. More and more reports have revealed that SOX9 is involved in various human cancers. In this study, we aimed to explore the relationship between SOX9 expression and diagnostic value of PCa patients. Methods In this study, quantitative real-time PCR (qRT-PCR) was performed to determine the expression of SOX9 of the 131 PCa patients and 74 healthy volunteers. And receiver operating characteristic (ROC) curve was used to determine the diagnostic value of SOX9 for PCa patients. Results The results of qRT-PCR showed that the expression of serum SOX9 in PCa patients was higher than that in healthy controls (P < 0.05). And the expression of SOX9 was significantly associated with PSA (P = 0.001), differentiation (P = 0.000), and lymph node metastasis (P = 0.000). Besides, the area under the ROC curve (AUC) was 0.966 with the sensitivity of 93.2% and specificity of 87.8% respectively. The optimal cutoff value of SOX9 was 2.34. Conclusions Our results found that SOX9 is a novel oncogene for PCa, and may be a novel and effective biomarker for the diagnosis of patients with PCa.

scholarly journals Identification of Circulating MiR-25 as a Potential Biomarker for Pancreatic Cancer Diagnosis

2016 ◽  
Vol 39 (5) ◽  
pp. 1716-1722 ◽  
Author(s):  
Ting Deng ◽  
Yaozong Yuan ◽  
Chunni Zhang ◽  
Chenyu Zhang ◽  
Weiyan Yao ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Diagnosis ◽  
Diagnostic Value ◽  
Serum Tumor Marker ◽  
Quantitative Real Time Pcr ◽  
Serum Samples ◽  
Qrt Pcr ◽  
Potential Biomarker ◽  
Potential Use ◽  
Normal Controls

Background: The aim of this study was to identify novel microRNAs for potential use in the diagnosis of pancreatic cancer (PaC). Methods: A total of 1063 serum samples from 303 patients with PaC were collected, and the expression level of miR-25 was measured using quantitative real-time PCR (qRT-PCR). Results: We found that miR-25 had significant diagnostic value for the differential diagnosis of PaC in normal controls with an AUC (the area under the ROC curve) of 0.915 (95% CI: 0.893-0.937) that was significantly higher compared with an AUC of 0.725 for serum tumor marker carcinoembryonic antigen (CEA) and an AUC of 0.844 for CA19-9. Conclusions: These data suggest that serum miR-25 has strong potential as a novel biomarker for the early detection of PaC.

scholarly journals Circulating exosomal lncRNAs in patients with chronic coronary syndromes

2021 ◽  
Author(s):  
Meili Zheng ◽  
Ruijuan Han ◽  
Wen Yuan ◽  
Hongjie Chi ◽  
Yeping Zhang ◽  
...  
Keyword(s):  
Operating Characteristic ◽  
Case Control Study ◽  
Diagnostic Value ◽  
Pcr Analysis ◽  
Roc Curve Analysis ◽  
Coronary Syndrome ◽  
Qrt Pcr ◽  
Coronary Syndromes ◽  
European Society Of Cardiology ◽  
Control Study

IntroductionThe concept of chronic coronary syndrome (CCS) was first presented at the European Society of Cardiology Meeting in 2019. However, the roles of exosomal lncRNAs in CCS remain largely unclear.Material and methodsA case-control study was performed with a total of 218 participants (137 males and 81 females), including 15 CCS patients and 15 controls for sequencing profiles, 20 CCS patients and 20 controls for the first validation, and 100 CCS patients and 48 controls for the second validation. Exosomes were isolated from the plasma of CCS patients and controls, and exosomal lncRNAs were identified by sequencing profiles and verified twice by qRT-PCR analysis. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic value of exosomal lncRNAs for CCS patients.ResultsA total of 152 significantly differentially expressed lncRNAs with over two-fold changes were detected in plasma exosomes of CCS patients, including 90 upregulated and 62 downregulated lncRNAs. Importantly, 6 upregulated lncRNAs with the top fold changes were selected for validations. Exosomal lncRNAs ENST00000424615.2 and ENST00000560769.1 were significantly elevated in CCS patients in both validations compared with controls. The areas under the ROC of lncRNAs ENST00000424615.2 and ENST00000560769.1 were 0.654 and 0.722, respectively. Additionally, exosomal lncRNA ENST00000560769.1 was significantly higher in the CCS patients with more diseased vessels (p = 0.028).ConclusionsExosomal lncRNA ENST00000424615.2 and ENST00000560769.1 were identified as novel diagnosis biomarkers for patients with CCS. Moreover, exosomal lncRNA ENST00000560769.1 was significantly higher in the CCS patients with more diseased vessels, and might be associated with a poor prognosis.

scholarly journals Tumor-Derived Exosomal Long Noncoding RNAs as Promising Diagnostic Biomarkers for Prostate Cancer

2018 ◽  
Vol 46 (2) ◽  
pp. 532-545 ◽  
Author(s):  
Yu-Hui Wang ◽  
Jia Ji ◽  
Bi-Cheng Wang ◽  
Hao Chen ◽  
Zhong-Hua Yang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Tumor Invasion ◽  
Operating Characteristic ◽  
Specific Antigen ◽  
Roc Curves ◽  
Diagnostic Value ◽  
Healthy Individuals ◽  
Diagnostic Biomarkers ◽  
Non Invasive ◽  
Non Coding Rnas

Background/Aims: Exosomal circulating long non-coding RNAs (lncRNAs) in blood are emerging as clinically useful and non-invasive biomarkers for tumor diagnosis. However, normal cells can also secrete exosomes, so it is a prerequisite to obtain tumor-derived exosomes for better understanding of their diagnostic impacts in cancer. In this study, a dual-antibody-functionalized immunoaffinity system was established to isolate exosomes and investigate their lncRNAs expression pattern and clinical significance in prostate cancer (PCa). Methods: A commercially available kit was used to isolate total exosomes, which were then purified by a dual-antibody-functionalized immunoaffinity system. RT-qPCR was performed to detect the expression of exosomal lncRNAs. Receiver operating characteristic (ROC) curves were plotted to assess the diagnostic value. Results: Expression levels of two lncRNAs in tumor-derived exosomes were significantly higher than those in total exosomes. The levels of SAP30L-AS1 were upregulated in benign prostatic hyperplasia (BPH), and SChLAP1 levels were significantly higher in PCa than in BPH and healthy individuals. The area under the ROC curve indicated that SAP30L-AS1 and SChLAP1 had adequate diagnostic value to distinguish PCa from controls. Two lncRNAs separately combined with prostate specific antigen (PSA) possessed a moderate ability for discrimination. SAP30L-AS1 expression level was related to PSA values and tumor invasion. SChLAP1 expression was significantly higher in patients with higher Gleason scores, and was also effective in differentiating between BPH and PCa when the concentration of PSA was in the gray zone. Conclusion: The isolation of tumor-derived exosomes by dual-antibody-functionalized immunoaffinity systems and detection of their lncRNAs in plasma may lead to the identification of suitable biomarkers, with potential diagnostic utility.

scholarly journals Serum exosomal miR-451a acts as a candidate marker for pancreatic cancer

2022 ◽  
pp. 172460082110700
Author(s):  
Jia Chen ◽  
Dongting Yao ◽  
Weiqin Chen ◽  
Zhen Li ◽  
Yuanyuan Guo ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patients ◽  
Diagnostic Marker ◽  
Clinical Stage ◽  
Benign Disease ◽  
Diagnostic Efficiency ◽  
Healthy Individuals ◽  
Serum Samples ◽  
Exosomal Mirnas ◽  
Serum Exosomes

Objectives The aim of this study was to explore the diagnostic efficiency of serum exosomal miR-451a as a novel biomarker for pancreatic cancer. Methods Serum samples were collected prior to treatment. First, we analyzed microRNA (miRNA) profiles in serum exosomes from eight pancreatic cancer patients and eight healthy volunteers. We then validated the usefulness of the selected exosomal miRNAs as biomarkers in another 191 pancreatic cancer patients, 95 pancreatic benign disease (PB) patients, and 90 healthy controls. Results The expression of miR-451a in serum-derived exosomes from pancreatic cancer patients was significantly upregulated compared with those from PB patients and healthy individuals. Serum exosomal miR-451a showed excellent diagnostic power in identifying pancreatic cancer patients. In addition, exosomal miR-451a showed a significant association with clinical stage and distant metastasis in pancreatic cancer, and the expression level of serum exosomal miR-451a was sensitive to therapy and relapse. Conclusions Serum exosomal miR-451a might serve as a novel diagnostic marker for pancreatic cancer.

scholarly journals ENO1 Overexpression in Pancreatic Cancer Patients and Its Clinical and Diagnostic Significance

2018 ◽  
Vol 2018 ◽  
pp. 1-7 ◽  
Author(s):  
Hang Yin ◽  
Lei Wang ◽  
Hai-Lin Liu
Keyword(s):  
Pancreatic Cancer ◽  
Lymph Node ◽  
Poor Prognosis ◽  
Diagnostic Marker ◽  
Clinical Stage ◽  
Healthy Controls ◽  
Diagnostic Significance ◽  
Node Metastasis ◽  
Homogeneous Assay ◽  
Electrochemiluminescence Immunoassay

We investigated in this study the expression of ENO1 in tissues and plasma of PDAC patients to evaluate its clinicopathological and diagnostic significance. ENO1 protein expression was detected in tissue microarray of human PDAC and adjacent noncancer tissues. Electrochemiluminescence immunoassay and amplified luminescent proximity homogeneous assay (AlphaLISA) were performed to measure CA19-9 and ENO1 concentration in plasma from PDAC patients and healthy controls. We demonstrated that ENO1 overexpression is positively correlated with clinical stage, lymph node metastasis, and poor prognosis of PDAC; ENO1 may function as a hopeful candidate diagnostic marker in combination with CA19-9 in PDAC diagnosis.

Sign in / Sign up

Export Citation Format

Share Document